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Abstract
Introduction: The irregular vasculature of solid tumors creates hypoxic regions, which are characterized by cyclic
periods of hypoxia and reoxygenation. Accumulated evidence suggests that chronic and repetitive exposure to
hypoxia and reoxygenation seem to provide an advantage to tumor growth. Although the development of
hypoxia tolerance in tumors predicts poor prognosis, mechanisms contributing to hypoxia tolerance remain to be
elucidated. Recent studies have described a subpopulation of cancer stem cells (CSC) within tumors, which have
stem-like properties such as self-renewal and the ability to differentiate into multiple cell types. The cancer stem
cell theory suggests CSCs persist in tumors as a distinct population and cause relapse and metastasis by giving rise
to new tumors. Since hypoxia is considered to be one of the critical niche factors to promote invasive growth of
tumors, we hypothesize that repetitive cycles of hypoxia/reoxygenation also play a role in the enrichment of breast
CSCs.
Methods: Two metastatic human breast cancer cell lines (MDA-MB 231 and BCM2) were used to optimize the
conditions of hypoxia and reoxygenation cycles. The percentage of CSCs in the cycling hypoxia selected
subpopulation was analyzed based on the CD44, CD24, ESA, and E-cadherin expression by three-color flow
cytometry. Colony formation assays were used to assess the ability of this subpopulation to self-renew. Limiting
dilution assays were performed to evaluate the tumor-initiating and metastatic ability of this subpopulation.
Induction of EMT was examined by the expression of EMT-associated markers and EMT-associated microRNAs.
Results: Using an optimized hypoxia and reoxygenation regimen, we identified a novel cycling hypoxia-selected
subpopulation from human breast cancer cell lines and demonstrated that a stem-like breast cancer cell
subpopulation could be expanded through repetitive hypoxia/reoxygenation cycles without genetic manipulation.
We also found that cells derived from this novel subpopulation form colonies readily, are highly tumorigenic in
immune-deficient mice, and exhibit both stem-like and EMT phenotypes.
Conclusions: These results provide the validity to the newly developed hypoxia/reoxygenation culture system for
examining the regulation of CSCs in breast cancer cell lines by niche factors in the tumor microenvironment and
developing differential targeting strategies to eradicate breast CSCs.
Introduction
Recent studies have described a subpopulation of cancer
cells within tumors termed ‘cancer stem cells’ (CSCs),
which have stem-like properties such as self-renewal and
the ability to differentiate into multiple cancer cell types
[1-7]. The CSC theory suggests that such CSCs persist in
tumors as a distinct population and cause relapse and
metastasis by giving rise to new tumors [8-10]. Although
CSCs make up only a small fraction of a tumor, they pos-
sess the unique capability to regenerate a tumor whereas
most tumor cells lack this regenerative capability [11,12].
By means of a non-obese diabetic/severe combined
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assay in combination with specific cell surface markers
(CD44
+CD24
-/low), CSCs were enriched from metastatic
and primary breast tumors and were shown to have the
ability to reestablish tumor heterogeneity after transplan-
tation [1]. Since then, additional CSC markers have been
proposed and studied to isolate putative tumor stem cell
populations. However, as demonstrated by a recent
report from Stuelten and colleagues [13], the complexity
of CSC markers continues to pose challenges for identify-
ing and isolating the putative tumor stem cell popula-
tions by the cell-sorting approach. In addition to
initiating tumors, CSCs are thought to be capable of initi-
ating metastasis. The link between CSCs and metastasis
has been suggested by several studies. First, breast CSCs
were shown to invade through Matrigel, a basement
membrane matrix used routinely as an indicator of meta-
static potential of cancer cells [14]. Second, a recent
study demonstrated that there is a link between epithe-
lial-mesenchymal transition (EMT) and breast CSCs [15].
Furthermore, the prevalence of CD44
+CD24
- cells in
breast cancer patients indicates a link between high
numbers of stem-like cancer cells and metastasis [16].
However, only a few studies have directly tested the
metastatic capability of putative CSCs in vivo. Collective
evidence from a few studies that directly tested the
in vivo metastasis using sorted CSCs suggests that
the CSC phenotype alone may exhibit invasive property
in vitro but is inadequate to determine or predict in vivo
metastasis. For example, in pancreatic cancer, CSCs
(CD133
+ cells) were not able to metastasize when
injected orthotopically at low numbers [17]. In mammary
carcinomas, CD44
+CD24
low cells were invasive in vitro
but the phenotype was not sufficient for metastasis when
cells were injected intracardiacally in vivo [14]. Therefore,
we set out to investigate alternative mechanisms that
could enrich for breast CSCs with tumor-initiating and
metastatic capabilities.
To identify factors that distinguish the malignant
subpopulation within breast tumors, we began to explore
environmental influences known to associate with
aggressively metastatic breast tumors. It has been postu-
lated that hypoxia contributes directly to the develop-
ment of more aggressive cancers by exerting selective
pressure on the tumor cell population to favor cells that
can survive decreased O2 and nutrients [18-20]. During
tumor development, rapid expansion of cancer cells cre-
ates a hypoxic microenvironment that is followed by per-
iods of reoxygenation to promote tumor progression.
These two aspects of tumor progression (hypoxia and
reoxygenation) cooperate to provide growth advantages
essential for the progressive development of aggressive
tumors [21]. Although extensive efforts have been
devoted to understanding the effect of hypoxia on tumor
progression, two areas of tumor biology remain unclear.
What is the effect of fluctuating oxygen tension on
tumor progression? How does hypoxia drive an irreversi-
ble phenotype without genetic manipulation? It is known
that both hypoxia and consecutive hypoxia/reoxygena-
tion can exert a variety of effects on tumor cell biology,
including activation of pro-survival signal transduction
pathways, aberrant genetic and epigenetic alterations,
and increased tumor angiogenesis. In some studies,
hypoxia/reoxygenation was shown to drive expression of
proteins associated with poor prognosis [22]. Further-
more, susceptibility of genomic instability can vary after
acute or chronic exposure to hypoxia followed by reoxy-
genation [23]. Therefore, we hypothesize that hypoxia/
reoxygenation cycles may provide the driving force to
select for a highly metastatic breast CSC subpopulation.
To study the effect of hypoxia/reoxygenation cycles
on breast cancer, we exposed two metastatic human
breast cancer cell lines (MDA-MB 231 and BCM2) to
cycles of chronic hypoxia and nutrient deprivation.
After one cycle of hypoxia and reoxygenation, we
observed a small cell population that survived hypoxia
as spherical clusters under hypoxic conditions and that
resumed proliferation after reoxygenation. We then iso-
lated and exposed this novel subpopulation to additional
cycles of hypoxia/reoxygenation and established a dis-
tinct subpopulation of cells from these two breast can-
cer cell lines. As expected, this novel subpopulation
showed increasing viability under hypoxia and the abil-
ity to proliferate as either an adherent monolayer or
substrate-independent tumor spheres. Interestingly, an
increased fraction of the cell population was found to
express CD44
+/CD24
-/ESA
+ cell surface markers. How-
ever, this novel subpopulation was distinguished by
being highly tumorigenic and metastatic and showed
upregulation of EMT markers. These findings strongly
suggest that we have succeeded in isolating a unique
metastatic CSC population by exposing breast cancer
cells to repetitive cycles of hypoxia and reoxygenation.
Materials and methods
Cell lines and tissue culture
MDA-MB 231 was purchased from American Type Cul-
ture Collection (Manassas, VA, USA); BCM2 cell line
was obtained from Brunhilde Felding-Habermann
(Scripps Research Institute, La Jolla, CA, USA). MDA-
MB 231 and BCM2 cell lines were cultured in minimum
essential medium (MEM) (Invitrogen Corporation,
Carlsbad, CA, USA) supplemented with 10% fetal bovine
s e r u m( H y C l o n e ,L o g a n ,U T ,U S A ;T h e r m oF i s h e r
Scientific Inc., Waltham, MA, USA), 2 mM L-glutamine,
1 mM sodium pyruvate, 1 mM non-essential amino
acids, and 1% vitamin (HyClone). All cell lines were
grown at 37°C and in 5% carbon dioxide.
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Non-confluent cultures were trypsinized into single-cell
suspension, counted, washed with phosphate-buffered
saline (PBS), and fixed with 10% paraformaldehyde. Cells
were stained with antibodies specific for human cell sur-
face markers: CD326/ESA-FITC, CD24-PE, and CD44-
PE-Cy7 (BD Pharmingen, San Jose, CA, USA). E-cadherin
antibody was purchased from Cell Signaling Technology,
I n c .( D a n v e r s ,M A ,U S A ) .At o t a lo f2×1 0
5 cells were
incubated with antibodies for 30 minutes on ice.
Unbound antibody was washed, and cells were analyzed
on a Guava EasyCyte Plus Flow Cytometer (Millipore
Corporation, Billerica, MA, USA). The Student t test was
used to calculate the significance of increased CD44
+/CD24
-/ESA
+ and E-cad
-/CD44
+/CD24
- populations in
the cycling hypoxia-selected subpopulations.
Viability and cell proliferation assay
Cells were collected from either the media (floating subpo-
pulation) or the adherent subpopulation after each
hypoxic cycle and dissociated into single-cell suspension
by trypsin/EDTA (trypsin/ethylenediaminetetraacetic
acid). Guava ViaCount Reagent (Millipore Corporation)
was used to determine the viability and cell numbers after
each hypoxic cycle. For cell proliferation assay, 5 × 10
4
cells were seeded in triplicate wells per cell line per time
point in 12-well tissue culture plates. Cells were detached
(adherent culture) or dissociated (spherical culture) by
trypsin/EDTA and resuspended in PBS for cell counting
using the ViaCount assay. In accordance with the manu-
facturer’s instructions, an appropriate volume of the
ViaCount Reagent was mixed with 50 μLo fc e l ls u s p e n -
sion in PBS. After 5 minutes of incubation at room tem-
perature in the dark, ViaCount/cell mixture was loaded
into a 96-well microtiter plate and read by the Guava Flow
Cytometer. Both live and dead cells were detected and dis-
played in dot plots. The Guava ViaCount software carried
out calculation of viability and cell numbers for each sam-
ple automatically.
Colony-forming assays
For the colony formation assay, cells were trypsinized to
generate single-cell suspensions and counted by a hemo-
cytometer. Single-cell suspensions (500 cells per well)
were plated on 96-well plates with an ultralow attach-
ment surface. Three wells were seeded for each cell line,
and triplicate experiments were performed per cell line
(n =3 ) .T h eE V O Sm i c r o s c o p e( A d v a n c e dM i c r o s c o p y
Group, Bothell, WA, USA) was used to count tumor
spheres and take images of each well on days 1, 3, 5, and
9. Immediately after the cells were seeded, each well was
checked under the microscope to verify the sparseness of
each spherical culture, and only wells containing single-
cell suspension with no cell cluster were chosen for
tumor-sphere counting after 9 days. Colonies of at least
60 μm in diameter (determined by using an eyepiece gra-
ticule with crossed scales) were counted on day 9 after
plating. Colony-forming efficiency (CFE) was calculated
by dividing the number of colonies (> 60 μm) formed by
the original number of single cells seeded and is
expressed as a percentage.
Animals and surgery
All animal procedures were performed in accordance with
an approved protocol by the Stony Brook University Insti-
tutional Animal Care and Use Committee. NOD/SCID
mice were purchased from the Jackson Laboratory (Bar
Harbor, ME, USA). Four- to six-week-old female mice
were used for tumor injections. Human breast cancer cells
were suspended in sterile Hank’sb u f f e r e ds a l ts o l u t i o n
(HBSS) and injected into the third thoracic mammary
gland. Tumor formation was assessed by palpation at least
once a week. A caliper was used to measure the length
and width of tumors at least once a week. A standard for-
mula for calculating tumor volume (in cubic millimeters)
was used: length × (width)
2/2. Duplicate experiments were
performed for each cell number.
Quantification of lung metastasis
Five to six weeks after the resection of primary tumors
from tumor-bearing NOD/SCID mice, lungs were har-
vested and fixed in the Bouin’s fixative solution overnight.
Nodules on the surface of lungs were visualized under the
dissecting microscope, and a USB digital camera (Leica
Microsystems, Bannockburn, IL, USA) from the micro-
scope was used to take gross images of each lung. To
quantify the tumor burden, each image was first annotated
with the National Institutes of Health ImageJ software to
identify measurable nodules on the surface of the lung.
The length and width of each nodule were measured with
pixels and then converted to millimeters to calculate the
tumor volume. A standard formula for calculating tumor
volume (cubic millimeters) was used: length × (width)
2/2.
Metastatic tumor burden of each animal was calculated by
combining tumor volumes from four lobes of lungs. Aver-
age tumor burden and standard deviations were derived
from at least four animals per group.
Western blot analysis
Subcellular fractionation of cell lysates was prepared
using the ProteoExtract Subcellular Proteome Extraction
Kit (Calbiochem-EMD Biosciences, San Diego, CA,
USA), and protein concentrations were determined by
EZQ Protein Quantification Kit (Invitrogen Corporation).
Proteins from nuclear or cytoplasmic fractions (40 μg)
were resolved by 4% to 20% SDS-PAGE and transferred
onto nitrocellulose membranes for immunoblotting.
Immunoblotting assays were carried out by standard
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and vimentin antibodies (Novus Biologicals, Littleton,
CO, USA). Anti-b-actin antibody (Sigma-Aldrich, St.
Louis, MO, USA) was used to confirm equal protein
loading of cytoplasmic fractions. Anti-histone H3 anti-
body (Millipore Corporation) was used to confirm equal
protein loading of nuclear fractions. Secondary antibodies
conjugated with either AF680 (Invitrogen Corporation)
or CW800 (LI-COR Biosciences, Lincoln, NE, USA) were
used to visualize protein bands using the Odyssey Infra-
red Imager (LI-COR Biosciences).
Analysis of the mRNA and microRNA expression by
quantitative reverse transcription-polymerase chain
reaction assay
Total RNA was isolated from each cell line using an RNA
Extraction Kit (Qiagen Inc., Valencia, CA, USA) in accor-
dance with the manufacturer’s instructions. One point two
micrograms of total RNA from each cell line was reverse-
transcribed using random primers and the High-Capacity
cDNA Synthesis Kit (Applied Biosystems, Foster City, CA,
USA). The resulting cDNAs were mixed with the SYBR
PCR [polymerase chain reaction] master mix (Applied Bio-
systems) and run on the StepOnePlus Applied Biosystems
Real-time PCR machine. One cycle of denaturing step
(10 minutes at 95°C) was applied, followed by 35 cycles of
amplification (15 seconds at 95°C and 1 minute at 58°C),
with fluorescence measured during the extension. Primers
used to amplify the human Snail gene have the following
sequences: 5’-CCTCCCTGTCAGATGAGGAC-3’ (for-
ward) and 5’-CCAGGCTGAGGTATTCCTG-3’ (reverse).
Primers used to amplify the human Slug gene have the fol-
lowing sequences: 5’-GGGGAGAAGCCTTTTTCTTG-3’
(forward) and 5’-TCCTCATGTTTGTGCAGGAG-3’
(reverse). Primers used to amplify the human Twist gene
have the following sequences: 5’-GGAGTCCGCAGTCT-
TACGAG-3’ (forward) and 5’-TCTGGAGGACCTGGTA-
GAGG-3’ (reverse). The relative quantification (RQ) value
reflects the fold changes of mRNA expression in each cell
line compared with the parental cell lines. RQ was calcu-
lated using the comparative CT (ΔΔCT) method and Ste-
pOne software version 2.0.1 (Applied Biosystems) and
normalized by the expression of the housekeeping gene,
GAPDH (glyceraldehyde-3-phosphate dehydrogenase).
Three independent experiments were performed to derive
average RQ and standard deviations (n =3 ) .
For microRNA (miRNA) analysis, total RNAs, includ-
ing miRNAs, were isolated from the cell lines using TRI-
zol reagent (Invitrogen Corporation) in accordance with
the manufacturer’s instructions. Ten nanograms of total
RNA from each cell line was converted to cDNA using
the High-Capacity cDNA synthesis kit (Applied Biosys-
tems). The miRNA sequence-specific reverse transcrip-
tion-PCR (RT-PCR) primers for miR-200c, miR-205, and
an endogenous control RNU6B were purchased from
Ambion (Austin, TX, USA). Real-time quantitative RT-
PCR (qRT-PCR) analysis was performed using the 7500
Real-Time PCR System from Applied Biosystems. The
TaqMan master mix was added to the cDNA and primer
mix to amplify and quantify target miRNAs (No AmpEr-
ase UNG; Applied Biosystems). The following PCR cycle
was used for miRNA amplifications: 95°C for 10 minutes
and 40 cycles of 95°C for 15 seconds and 60°C for 60 sec-
onds. The RQ value reflects the fold changes of miRNA
expression in each cell line compared with the parental
cell lines. RQ was calculated using the comparative CT
(ΔΔCT) method and StepOne software version 2.0.1
(Applied Biosystems) and normalized by the expression
of the internal control RNU6B. Three independent
experiments were performed to derive average RQ and
standard deviations (n = 3).
Results
Establishing optimized conditions for hypoxia and
reoxygenation selection
To study the effect of repetitive hypoxia/reoxygenation
on breast cancer cells, we optimized conditions of
hypoxia and reoxygenation with regard to the number
of cycles, exposure time, cell numbers, and other para-
meters. We used two metastatic breast cancer cell lines,
MDA-MB 231 and BCM2 [24], to ensure that our
current protocol was not cell line-specific. To establish
efficient and reproducible hypoxia/reoxygenation condi-
tions, we used the ProOxC system (BioSpherix, Lacona,
NY, USA), which allows precise oxygen control over an
extended time period via an oxygen sensor and auto-
matic feedback mechanisms to maintain a consistently
low oxygen environment. The optimized procedure
included exposing these breast cancer cell lines (1 × 10
7
cells in a T125 tissue culture flask, approximately 60%
confluency) to hypoxia (1% O2) and nutrient deprivation
for 7 days, mimicking the avascular microenvironment,
and reoxygenating surviving cells for 1 to 3 weeks
depending on the viability of surviving cells (Figure 1).
The same growth media used to maintain monolayer
cultures (see Materials and methods) were used to
prepare the cells and maintain the adherent and non-
adherent cells in culture. After each hypoxic cycle, 10%
of the adherent culture became non-adherent (floating
cell population). Using this protocol, we consistently
observed novel surviving populations that were non-
adherent and that demonstrated a propensity to form
spherical clusters under hypoxic conditions. However,
unlike the adherent hypoxia-resistant cells, only 10% of
t h et o t a ln o n - a d h e r e n tc e l l sw e r ev i a b l ea f t e rt h ef i r s t
round of hypoxic cycle (F1). After reoxygenating and
growing F1 cells as spherical cultures, we exposed the
same amount of F1 cells to a second hypoxic cycle and
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rounds of hypoxia and oxygenation, we found that the
viability of the non-adherent cells increased to 70% (F3).
Additional rounds of hypoxia did not increase the per-
centage of survival significantly. In addition to finding
increased hypoxia viability, we found distinct character-
istics in this novel subpopulation. For comparison pur-
poses, we exposed the adherent hypoxia-resistant cells
to two additional rounds of hypoxia/reoxygenation
selection and generated the hypoxia-exposed adherent
cell population (A3).
The newly isolated cycling hypoxia-selected breast cancer
subpopulation has increased tumor-initiating capability
Since hypoxia has been implicated in the promoting of
aggressive tumors, we first examined the tumor-initiat-
ing ability of the parental and newly isolated cycling
hypoxia-selected subpopulation in immune-deficient
mice. We orthotopically injected either parent MDA-
MB 231 and BCM2 or the cycling hypoxia-selected sub-
populations (MDA-MB 231 F3 and BCM2 F3) into
NOD/SCID mice as a limiting dilution assay from 5 ×
10
5 to 5 × 10
2 cells per mammary gland. Although there
was no noticeable difference in the frequency of tumor
formation between these two cell populations (MDA-
MB 231 and MDA-MB 231 F3) when 5 × 10
5 cells were
injected, a dramatic difference in tumor initiation and
growth was observed when 10-fold, 100-fold, and 1,000-
fold fewer cells were injected in NOD/SCID mice
(Figure 2a). With as few as 500 cells, MDA-MB 231 F3
a n dB C M 2F 3c e l l sc o u l df o r mt u m o r si nN O D / S C I D
mice, whereas both parent cell lines were not able to do
so at the same dilution (Table 1 and Figure 2b,c).
Furthermore, tumors progressed rapidly in mice injected
with lower numbers of MDA-MB 231 F3 cells and
BCM2 F3 cells (5 × 10
4 cells) than equivalent numbers
of MDA-MB 231 cells (Figure 2a-c), indicating that
MDA-MB 231 F3 cells formed more aggressive tumors.
We also injected 500 hypoxia-exposed adherent cells
(MDA-MB 231 A3 and BCM2 A3) in the mammary fat
pad of female NOD/SCID mice. None of the mice
injected with 500 MDA-MB 231 A3 or BCM2 A3 cells
developed mammary tumors by 90 days (MDA-MB 231
A 3 )o r9 8d a y s( B C M 2A 3 )( T a b l e1 ) .W ec o n c l u d e
that the newly isolated cycling hypoxia-selected non-
adherent subpopulation is highly tumorigenic compared
with the hypoxia-exposed adherent and parental cell lines.
The newly isolated cycling hypoxia-selected breast cancer
subpopulation comprises putative breast cancer stem cell
population (CD44
+/CD24
-/ESA
+)
Evidence of stem-like cancer cells has been established
in various types of cancer, including breast cancer
[1,3,4,7,8,12,25]. This small subpopulation has been
shown to be highly tumorigenic and exhibits some stem
cell characteristics such as self-renewal and the ability to
form tumor spheres [12,26]. Since the newly isolated
cycling hypoxia-selected subpopulation is highly tumori-
genic, we hypothesized that this subpopulation is
enriched with stem-like breast cancer cells. Using the
three-color flow cytometry analysis, we found that the
cycling hypoxia-selected subpopulation displayed an
increased proportion of cells with the surface marker
expression of CD44
+/CD24
-/ESA
+, which has been
reported as putative breast CSCs. The percentage of the
CD44
+/CD24
-/ESA
+ cell population was significantly
increased in the cycling hypoxia-selected subpopulation
in comparison with the parental breast cancer cell lines
(3-fold increase in MDA-MB 231 F3 cells, Figure 3a,c;
13-fold increase in BCM2 F3, Figure 3b,c; Figure S1 in
Additional file 1). Since it has been reported that
hypoxia exposure alone can increase the stem-like cell
Figure 1 An illustration of the hypoxia and reoxygenation regimen. Conditions for hypoxia/reoxygenation cycles were optimized using two
human metastatic breast cancer cell lines (MDA-MB 231 and BCM2). The viability of non-adherent cells is listed after each hypoxic cycle. FBS,
fetal bovine serum.
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+/
CD24
-/ESA
+ and CD44
+/CD24
+/ESA
+ cell populations
in the hypoxia-exposed adherent cells (MDA-MB 231
A3 and BCM2 A3) and found only a slight increase in
the percentage of CD44
+/CD24
-/ESA
+ cell population in
the hypoxia-exposed adherent cells compared with the
parental breast cancer cell lines (1.8-fold increase in
MDA-MB 231 A3 cells, Figure 3c; 3.5-fold increase in
Figure 2 Growth curves of primary tumors generated from the parental cell lines and cycling hypoxia-selected subpopulations. (a)
Growth curves of primary tumors in non-obese diabetic/severe combined immunodeficiency disease (NOD/SCID) mice injected with 5 × 10
5 or
5×1 0
4 MDA-MB 231 and MDA-MB 231 F3 cells. Tumors were first detected by palpation. Standard errors are derived from duplicate
experiments (n = 6 per cell number for each experiment). (b) Growth curves of tumors in NOD/SCID mice injected with 5 × 10
3 or 5 × 10
2
MDA-MB 231 and MDA-MB 231 F3 cells. Standard errors were derived from duplicate experiments (n = 5 per cell number for each experiment).
(c) Growth curves of tumors in NOD/SCID mice injected with 5 × 10
4 or 5 × 10
2 BCM2 and BCM2 F3 cells. Standard errors were derived from
duplicate experiments (n = 5 per cell number for each experiment).
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cancer cells in vivo
Cell type Days Number injected and tumors formed
5×1 0
5 5×1 0
4 5×1 0
3 5×1 0
2
MDA-MB 231 (total cell population) 24-90 5/6 2/6 0/5 0/5
MDA-MB 231 A3 (hypoxia-exposed adherent cells) 90 - - - 0/5
MDA-MB 231 F3 (cycling hypoxia-selected subpopulation) 10-90 6/6 6/6 5/5 4/5
BCM2 (total cell population) 35-98 - 5/5 - 0/5
BCM2 A3 (hypoxia-exposed adherent cells) 98 - - - 0/5
BCM2 F3 (cycling hypoxia-selected subpopulation) 28-98 - 5/5 - 4/5
Figure 3 Cell surface expression of ESA, CD44, and CD24. Three-color flow cytometry analysis was performed to detect the CD44
+/CD24
-/
ESA
+ cell population. (a) Top panel: Unstained, isotype control, and ESA-stained cells are shown in the histogram. ESA staining of MDA-MB 231
(total cell population) and MDA-MB 231 F3 (cycling hypoxia-selected subpopulation) cells. M1 marker gates ESA
+ cells, and M2 marker gates the
ESA
- cells. Bottom panel: CD44 and CD24 expression of ESA
+ cells in each cell line. The percentages of the CD44
+/CD24
- and CD44
+/CD24
+ cells
within the ESA
+ cell population are indicated in the Quad plot. (b) The same flow cytometry analysis for BCM2 (total cell population) and BCM2
F3 (cycling hypoxia-selected subpopulation) cells. (c) Quantitative comparison of CD44
+/CD24
-/ESA
+ cell population and CD44
+/CD24
+/ESA
+ cell
population in cycling hypoxia-selected subpopulations (MDA-MB 231 F3 and BCM2 F3) and their parental breast cancer cell lines. At least three
replications were performed to derive the average percentage of each cell population in each cell line and standard deviations. Asterisks indicate
statistical significance by two-tail t test (n =3 ,P < 0.05). ESA, epithelial-specific antigen.
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exposures of hypoxia and reoxygenation are crucial for
the enrichment of stem-like breast cancer cells in this
novel non-adherent subpopulation.
It has been shown that tumor-initiating cells or CSCs
resemble stem cells in their ability to grow as spheres
when cultured under conditions in which they cannot
attach to a solid substratum [6,27]. To test whether the
increased tumor-initiating capability observed in the
cycling hypoxia-selected subpopulations correlates with
their ability to grow as tumor spheres in culture, cells
from parental cell populations (MDA-MB 231 and
BCM2), hypoxia-exposed adherent cells (MDA-MB 231
A3 and BCM2 A3), and cycling hypoxia-selected subpo-
pulations (MDA-MB 231 F3 and BCM2 F3) were plated
at low density (500 cells per 0.32 cm
2)o n t ou l t r a l o w
attachment plates in MEM. Images of cells from each
well were taken at days 1, 3, 5, and 9 to visualize the
formation of colonies. After day 5, we noticed that the
appearance of compact and asymmetric solid tumor
spheres developed in all wells containing MDA-MB 231
F3 and BCM2 F3 cells whereas only small clusters of
cells were found in wells containing MDA-MB 231 and
BCM2 cells (Figure 4a). By day 9, we observed that
some large tumor spheres began to form in the parental
cell lines. The time line of tumor-sphere formation was
comparable between hypoxia-exposed adherent cells
( M D A - M B2 3 1A 3a n dB C M 2A 3 )a n dt h e i rp a r e n t a l
cell lines. To determine the CFE of each cell population,
tumor spheres of at least 60 μm were counted on day 9
after plating. CFE was calculated by dividing the number
of tumor spheres formed by the original number of sin-
gle cells seeded and was expressed as a percentage.
Three independent experiments were performed to
derive the average CFE and standard deviation per cell
line. Although there is around a 2-fold increase in CFE
in hypoxia-exposed cells (MDA-MB 231 A3 and BCM2
A 3 )c o m p a r e dw i t ht h ep a r e n t a lc e l ll i n e s ,al a r g e r
increase (7- to 8-fold) of CFE was found in the cycling
hypoxia-selected subpopulations compared with the par-
ental cell lines (Figure 4b). Therefore, according to our
results, the increased tumor-initiating capability of the
cycling hypoxia-selected subpopulations is in accordance
with the increased ability to grow as spherical colonies
in culture.
In addition to showing increased ability to grow as
spherical colonies, the stem-like cancer cells were
shown to proliferate slower than the bulk cancer cells
[28,29]. This attribute of stem-like cancer cells has sig-
nificant clinical implications such as chemoresistance
and radioresistance. To determine whether the cycling
hypoxia-selected subpopulations cycle slower than the
parental and hypoxia-exposed adherent cells, equal
numbers of cells from each cell population were plated
on day 1, and an increase in cell numbers over 5 days
was used to assess the rate of proliferation. To compare
the rate of proliferation under the same condition as the
parental and hypoxia-exposed adherent cells, we plated
the cycling hypoxia-selected subpopulation as adherent
cells (adherent MDA-MB 231 F3 and adherent BCM2
F3) and measured the increase in cell numbers together
with the other adherent cell populations. The prolifera-
tion of the cycling hypoxia-selected subpopulation as
spherical culture was performed separately. While the
parental and hypoxia-exposed adherent cells display
similar rates of proliferation, the cycling hypoxia-
selected subpopulations grow slower as adherent cells
a n de v e ns l o w e ra ss u s p e n s i o nc u l t u r e s( F i g u r e4 c ) .
Together, results from established assays for CSC activ-
ity show that the cycling hypoxia-selected subpopulation
has an increased ability of tumor initiation and tumor-
sphere formation. More importantly, these findings sug-
gested that our hypoxia/reoxygenation scheme resulted
in an enrichment of bona fide breast CSCs without
selecting for user-defined markers or targeted genetic
manipulation.
The newly isolated cycling hypoxia-selected breast cancer
subpopulation is highly metastatic and exhibits
increasing epithelial-mesenchymal transition phenotype
Aside from their role in tumor initiation, stem-like can-
cer cells have been hypothesized to contribute directly
to cancer metastasis. However, the collective evidence
from a few studies examining the metastatic potential of
CSCs in vivo suggests that CSC phenotype alone is not
enough to determine metastasis. Particularly, a study by
Sheridan and colleagues [14] demonstrates that CD44
+/CD24
- stem-like phenotype is not sufficient for hom-
ing and proliferation at sites of metastasis, despite a dis-
play of increased invasive property in vitro.
Using the human cancer cell xenograft model, we
were able to quantify lung metastases 4 weeks after the
surgical resection of primary tumors. Images of lungs
were taken by a digital camera built into the microscope
and were used for quantifying metastases. The National
Institutes of Health ImageJ software was used to mea-
sure the diameters (width and length) of each visible
metastasis on the lung, and total tumor volumes were
calculated from each animal (for a description, see
Materials and methods). Overall, lungs harvested from
mice with primary tumors derived from the cycling
hypoxia-selected MDA-MB 231 F3 cells showed signifi-
cantly more metastases than lungs harvested from mice
with parental cell primary tumors (Figure 5a). Mice
injected with 5 × 10
5 MDA-MB 231 F3 cells showed a
43-fold greater lung tumor burden, by volume, than
mice injected with 5 × 10
5 parental cells (Figure 5b).
Mice injected with 5 × 10
4 MDA-MB 231 F3 cells had
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Page 8 of 1476-fold greater lung tumor burden than mice injected
with 5 × 10
4 parental cells (Figure 5b). Remarkably,
mice injected with 100-fold and 1,000-fold less MDA-
MB 231 F3 cells showed a less than 10-fold reduction in
metastatic tumor burden, whereas this number of paren-
tal cells failed to form substantial metastases, indicating
that the cycling hypoxia-selected subpopulation is highly
metastatic in vivo.
Growing evidence demonstrates that many genes and
proteins known to play essential roles during embryonic
development are mutated or aberrantly expressed in
cancerous cells. One of the most widely studied regula-
tory programs that controls normal developmental pro-
cesses and contributes to tumor progression is the EMT
[30,31]. Recently, it was shown that inducing EMT
could generate mammary epithelial stem-like cells [15].
Furthermore, stem-like cancer cells exhibit EMT charac-
teristics such as the loss of E-cadherin, increased expres-
sion of fibronectin and vimentin, and increased
expression of mesenchymal transcription factors (Snail,
Twist, and Slug) [32-34]. Therefore, we speculated that
EMT plays a role in the increased tumorigenicity and
metastatic potential of the cycling hypoxia-selected sub-
population. Indeed, we found specific molecular changes
consistent with increased EMT in the cycling hypoxia-
selected F3 subpopulations. MDA-MB 231 F3 and
BCM2 F3 cells had an increased percentage of E-
cadherin-negative cell population (8% to 10% increase)
compared with the parental cell lines (Figure 6a; Figure
S1 in Additional file 1). Within the E-cadherin-negative
cell population, there was also an increased percentage
of CD44
+/CD24
- cell population in the F3 subpopula-
tions (27% increase in MDA-MB 231 F3 and 35%
increase in BCM2 F3) compared with the parental cell
lines (Figure 6b). Since the loss of E-cadherin is a hall-
mark of increased EMT, the cycling hypoxia-selected F3
subpopulations appear to be enriched with stem-like
and EMT cells.
Figure 4 The colony formation and proliferation of the parent cell lines and the cycling hypoxia-selected subpopulations. (a) Images of
colony formation assays from 500 cells of MDA-MB 231, MDA-MB 231 A3, MDA-MB F3, BCM2, BCM2 A3, and BCM2 F3 on days 1, 3, 5, and 9.
Representative images from three separate experiments are shown. (b) Colony-forming efficiency (CFE) of parental cells, hypoxia-exposed
adherent cells (MDA-MB 231 A3 and BCM2 A3), and the cycling hypoxia-selected subpopulations (MDA-MB 231 F3 and BCM2 F3). CFE was
determined when tumor spheres were larger than 60 μm in diameter on day 9 after plating. CFE was calculated by dividing the number of
tumor spheres formed by the original number of single cells seeded and is expressed as a percentage. Three independent experiments were
performed to derive the average CFE and standard deviation per cell line. Asterisk indicates statistical significance by two-tail t test (n =3 ,P <
0.05). (c) Proliferation curves of the parental cells, hypoxia-exposed cells (A3), and the cycling hypoxia-selected subpopulations grown as
adherent cultures (top two plots) or as spherical cultures (the third plot). Total viable cells from each well at days 3 and 5 were counted by the
ViaCount assay using the Guava Flow Cytometer. Average cell numbers and standard deviations at each time point were calculated from three
independent experiments.
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the transcriptional repression of E-cadherin. One of the
first discovered and most important transcriptional
repressors of E-cadherin is Snail [35]. Expression of
Snail represses expression of E-cadherin and induces
EMT in different cell types, including breast cancer cells
[36,37]. Therefore, we speculated that molecular
machinery found to promote EMT might also be upre-
gulated in the cycling hypoxia-selected subpopulation.
Consistent with a decrease inE - c a d h e r i ne x p r e s s i o n ,
MDA-MB 231 F3 and BCM2 F3 cells had increased
nuclear expression of Snail and cytoplasmic expression
of a mesenchymal marker vimentin (Figure 6c). Quanti-
tative analysis of Snail and vimentin protein expression
by Western blotting revealed a 3- to 4-fold increase in
nuclear Snail expression and an 8- to 9-fold increase in
vimentin expression in the MDA-MB 231 F3 and BCM2
F3 cells compared with the parental and hypoxia-
exposed A3 subpopulations (Figure 6c). Furthermore,
the cycling hypoxia-selected F3 subpopulations had
increased mRNA levels of three mesenchymal transcrip-
tion factors - Snail (7- to 10-fold), Slug (2- to 3-fold),
and Twist (2- to 4-fold) - as measured by qRT-PCR
(Figure 6d).
In addition to EMT-regulatory factors, regulatory mole-
cules such as miRNAs can play a role in promoting stem-
like and EMT phenotypes in cancer cells. Using a qRT-
PCR-based method, we found dramatic decreases of
epithelial miRNAs (miR200c and miR205) in the F3 sub-
populations compared with the parental breast cancer cell
lines (Figure 6e). It has been reported that human breast
CSCs and normal human mammary stem/progenitor cells
showed decreased expression of miR200c and other
miR200 members and that restoring miR200c in breast
CSCs inhibits their ability to expand clonally and form
tumors in vivo [38]. Hence, downregulation of miR200c
and miR205 in the cycling hypoxia-selected subpopulation
corroborates with the stem-like phenotype exhibited in
this subpopulation. In addition to miRNA200c and
miR205, the cycling hypoxia-selected subpopulation
showed decreased miR215 expression (Figure 6e). miR215
suppresses EMT by suppressing the mesenchymal tran-
scription factor ZEB2 and increasing the E-cadherin level
[39]. Therefore, downregulation of miR-215 could pro-
mote EMT phenotype in downregulation of E-cadherin
and promote EMT phenotype in the cycling hypoxia-
selected subpopulation. Together, our results reinforce the
idea that EMT and stem cell factors work cooperatively in
highly tumorigenic cancer subpopulations and raise inter-
esting questions about their contribution to the increased
metastatic capability observed in the cycling hypoxia-
selected subpopulation.
Discussion
Some studies have shown that external influences, such
as hypoxia, can drive a ‘reversible’ phenotype that can
enhance stem-like properties of cells to ensure survival
of the tumor. Also, hypoxia-inducible factors have been
shown to play a role in CSC self-renewal and tumor
growth. It was reported, for example, that CSC state
Figure 5 Lung metastases from the tumor-initiating assays.
(a) Representative images of lungs from tumor-bearing non-obese
diabetic/severe combined immunodeficiency disease (NOD/SCID)
mice are shown (n = 6). A higher magnification of lung metastases
derived from orthotopic injection of 5 × 10
5 MDA-MB 231 or MDA-
MB 231 F3 cells is shown in the lower right corner. (b) Quantitative
analysis of the metastatic tumor burden in the lung. Images of
lungs were taken using a digital microscope camera. Images were
imported into the National Institutes of Health ImageJ software for
quantitative analysis. The sum of metastatic tumor volume was first
calculated from four lobes of lungs per animal (see Materials and
methods), and the lung metastasis per group is presented as tumor
volume (cubic millimeters). The number of animals used per group
is listed in Table 1.
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transcription factor (HIF2a) in glioma cell lines [40].
However, only few studies showed or discussed the possi-
bility of establishing irreversible phenotypes through
cycling hypoxic exposure without genetic manipulation
[41,42]. In our study, we found that exposing metastatic
breast cancer cell lines to hypoxia and reoxygenation
cycles induces a unique subpopulation that is highly
metastatic and exhibits stem-like and EMT phenotypes.
Our results led us to speculate that there might be a
metastatic subpopulation within stem-like cancer cells
since other studies have shown that CSC phenotype
alone may exhibit invasive property in vitro but is inade-
quate to determine or predict in vivo metastasis.
Figure 6 Expression of epithelial-mesenchymal transition (EMT)-associated markers in the total cell population and the cycling hypoxia-
selected subpopulation. (a) Three-color fluorescence-activated cell sorting (FACS) analysis was performed to detect CD44CD24 expression profile
on the E-cadherin-negative cell population. Unstained, isotype control, and E-cadherin (E-cad)-stained cells are shown in the histogram. ESA
staining of MDA-MB 231 (total cell population) and MDA-MB 231 F3 (cycling hypoxia-selected subpopulation) cells is shown. M1 marker gates E-
cadherin-positive cells, and M2 marker gates the E-cadherin-negative cells. Bottom panel: CD44 and CD24 expression of E-cadherin-negative cells in
each cell line. The percentages of the CD44
+/CD24
- and CD44
+/CD24
+ cells are indicated in the Quad plot. (b) Quantitative comparison of E-cad
-/
CD44
+/CD24
- cell population and E-cad
-/CD44
+/CD24
+ cell population in cycling hypoxia-selected subpopulations (MDA-MB 231 F3 and BCM2 F3)
and their parental breast cancer cell lines. At least three replications were performed to derive the average percentage of each cell population in
each cell line and standard deviations among the replicates. (c) Expression of EMT-associated proteins in the parental cells (P), hypoxia-exposed
adherent cells (A3), and the cycling hypoxia-selected subpopulations (F3). Lysates from these two cell populations were fractionated on the basis of
the subcellular localization using the ProteoExtract Kit, and 40 μg of proteins was loaded for Western blotting. Beta-actin is used as the loading
control for the cytoplasmic fraction, and histone H3 is used as the loading control for the nuclear fraction. Western blot images (n = 3) are
quantified by National Institutes of Health ImageJ software and presented as fold increase in A3 and F3 cells compared with the parental cell lines.
(d) mRNA regulation of EMT transcription factors in the parental, A3, and F3 cells. Quantitative reverse transcription-polymerase chain reaction (qRT-
PCR) analyses were performed using specific primers to measure the mRNA expression of human Snail, Slug, and Twist genes in these three cell
populations. At least three replications (n = 3) were performed to derive the average percentage of each cell population in each cell line and
standard deviations among the replicates. (e) Expression of EMT-suppressing microRNAs (miRNAs) in the parental, A3, and F3 cells. qRT-PCR
analyses were performed using specific primers to measure the expression of miR200c and miR205. At least three replications (n = 3) were
performed to derive the average percentage of each cell population in each cell line and standard deviations among the replicates. Asterisks
indicate statistical significance by two-tail t test (P < 0.05) for all quantitative results. ESA, epithelial-specific antigen.
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notypes observed in the cycling hypoxia-selected subpo-
pulation are not reversible, because we obtained the same
molecular profile from this subpopulation by culturing
them as spherical cultures for several months in normal
oxygen content and culturing them as adherent cells (Fig-
ure S2 in Additional file 2).
Nevertheless, we believe hypoxia is only a partial driv-
ing force for the metastatic CSC enrichment. Our study
showed that reoxygenation might also play a role in
selecting stem-like breast cancer cells. The occurrence
of reoxygenation following hypoxic exposures of various
degrees is inherent in the dynamic nature of the tumor
vasculature [43,44]. Fluctuating oxygen tensions in
tumors could lead to reoxygenation-induced DNA
damage and potentially increased genomic instability
[45]. A hypoxia-dependent decrease in DNA repair
could lead to the accumulation of unrepaired lesions in
tumors and contribute to tumor progression [46]. A
recent study by Pires and colleagues [23] showed that
cells that are exposed acutely to hypoxia are able to
restart replication regardless of the presence of active
checkpoint response and reoxygenation-induced DNA
damage. However, chronic exposure of cells to hypoxia
induces disassembly of the replisome, preventing repli-
cation restart after reoxygenation [23]. In our study, we
found that the emergence of a small non-adherent sub-
population (approximately 1%) survived after the first
hypoxia/reoxygenation cycle and speculate that cyclic
exposures of hypoxia and reoxygenation may select for
the stem-like subpopulation with the ability to overcome
replication arrest whereas the majority of non-adherent
cells cannot. Also, as shown in our study, the surviving
cycling hypoxia-selected subpopulation acquires addi-
tional molecular advantages after exposure to several
cycles of hypoxia/reoxygenation.
Phillips and colleagues [47] reported that the non-adher-
ent population of monolayer cultures of breast cancer cells
has the ability to initiate mammosphere formation after
irradiation. Other groups have also reported that exposing
cancer cells to environmental factors such as serum depri-
vation or hypoxia alone can increase the stem-like pheno-
type or the number of stem-like cancer cells [40,48,49].
Collectively, our results support the idea that a stem-like
subpopulation in the tumor could expand selectively in
response to changes in the microenvironment. However, it
is unclear whether the same stem-like subpopulation or a
different one is generated by various conditions. To
compare the non-adherent population described by
Phillips and colleagues [47] and our F3 non-adherent sub-
population, we studied the expression level of Snail, an
EMT transcription factor, in these two cell populations.
Our results showed that the expression of Snail is robustly
increased in cycling hypoxia-selected F3 cells compared
with the non-nutrient-deprived floating cell population
and the parental cell lines (Figure S2 in Additional file 2).
Although our data indicate that these two cell populations
are not the same, it is possible that this small viable float-
ing cell population expands and gives rise to the F3 cell
population after exposing cancer cells to cycling hypoxia
and reoxygenation. We are currently exploring this possi-
bility and hope to elucidate the mechanism and relevance
of the cycling hypoxia-selected cell population in breast
cancer progression.
Conclusions
Although many studies have suggested the potential of
CSCs as the seeds for distal metastasis, few studies have
directly tested the metastatic capability of putative CSCs
in vivo. Collective evidence from a few studies that
directly tested the in vivo metastasis using sorted CSCs
suggests that the CSC phenotype alone may exhibit inva-
sive property in vitro but is not sufficient to determine or
predict in vivo metastasis. Here, we show that a non-
adherent, stem-like, and metastatic CSC-enriched subpo-
pulation could be isolated by exposing human metastatic
breast cancer cell lines to cycles of chronic hypoxia fol-
lowed by reoxygenation. Since very few studies have
demonstrated the formation of macro-metastasis from
low numbers of sorted CSCs and currently proposed
CSC markers might not be sufficient to identify all stem
cell populations [13], we believe that our study presents a
promising approach to isolate stem-like and metastatic
breast CSCs as opposed to the cell-sorting strategy based
on putative stem cell surface markers. Also, it will be of
great interest to investigate the possibility that repetitive
cycles of hypoxia/reoxygenation lead to the selective
expansion of a pre-existing metastatic CSC subpopula-
tion. Our results demonstrated the possibility of isolating
highly metastatic breast CSCs using the hypoxia/reoxy-
genation regimen we established. With the recent success
of identifying selective inhibitors targeting CSCs, we
believe that the newly isolated cycling hypoxia-selected
subpopulation may present a new opportunity for chemi-
cal screening and discovery of compounds with selective
toxicity for metastatic breast CSCs.
Additional material
Additional file 1: Figure S1. Gating parameters of ESA
+/CD24
-/CD44
+,
ESA
+/CD24
+/CD44
+, E-cad
+/CD24
-/CD44
+, and E-cad
+/CD24
+/CD44
+ cells
using the Guava EasyCyte Flow Cytometer.
Additional file 2: Figure S2. mRNA regulation of Snail in the parental,
non-nutrient deprived (Flo), cycling hypoxia-selected cells grown in
suspension culture (F3), and cycling hypoxia-selected cells grown in
monolayer culture (F3 AD). Quantitative qRT-PCR analyses were
performed using specific primers to measure the mRNA expression of
the human Snail gene. Minimum three replications (n = 3) were
performed to derive the average percentage of each cell population in
each cell line and standard deviations among the replicates.
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ethylenediaminetetraacetic acid; EMT: epithelial-mesenchymal transition; ESA:
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